86
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique

Pages 663-677 | Published online: 29 Sep 2008

References

  • AGUADO, M. T., and LAMBERT, P. H., 1992, Controlled-release vaccines—biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology, 184, 113–125.
  • ALONSO, M. J., GUPTA, R. K., MIN, C., SIBER, G. R., and LANGER, R., 1994, Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine, 12, 299–306.
  • BABA, E., NAKAMURA, M., TANAKA, Y., KUROKI, M., ITOYAMA, Y., NAKANO, S., and NIHO, Y., 1993, Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine. Journal of Immunology, 151, 1013–1024.
  • BAIN, D. F., MUNDAY, D. L., and SMITH, A., 1999, Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(3L-lactide). Journal of Microencapsulation, 16, 369–385.
  • BLANCO-PRIETO, M. J., FATTAL, E., PUISIEUX, F., and COUVREUR, P., 1998, New approaches for encapsulation of peptides into poly(lactic/glycolic acid) microspheres. Annales Pharmaceutiques Francaises, 56, 256–263.
  • CLELAND, J. L., and JONES, A. J., 1996, Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable micro-spheres. Pharmaceutical Research, 13, 1464–1475.
  • ELDRIDGE, J. H., HAMMOND, C. J., MEULBROEK, J. A., STAAS, J. K., GILLEY, R. M., and TICE, T. R., 1990, Controlled vaccine release in the gut-associated lymphoid tissues. 1. Orally administered biodegradable microspheres target the Peyer-s patches. Journal of Controlled Release, 11, 2105–2114.
  • ELDRIDGE, J. H., MEULBROEK, J. A., STAAS, J. K., TICE, T. R., and GILLEY, R. M., 1989, Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Advances in Experimental Medicine and Biology, 251, 191–202.
  • ELDRIDGE, J. H., STAAS, J. K., MEULBROEK, J. A., MCGHEE, J. R., TICE, T. R., and GILLEY, R. M., 1991b, Biodegradable microspheres as a vaccine delivery system. Molecular Immunology, 28, 287–294.
  • ELDRIDGE, J. H., STAAS, J. K., MEULBROEK, J. A., TICE, T. R., and GILLEY, R. M., 1991a, Biodegradable and biocompatible poly(m—lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infection and Immunity, 59, 2978–2986.
  • ERTL, H. C., VARGA, I., XIANG, Z. Q., KAISER, K., STEPHENS, L., and OTVOS, L. J., 1996, Poly(m—lactide-co-glycolide) microspheres as carriers for peptide vaccines. Vaccine, 14, 879–885.
  • Ho, P. C., MUTCH, D. A., WINKEL, K. D., SAUL, A. J., JoNEs, G. L., DORAN, T. J., and RZEPCZYK, C. M., 1990, Identification of two promiscuous T cell epitopes from tetanus toxin. European Journal of Immunology, 20, 477–483.
  • KAUMAYA, P. T., KOBS-CONRAD, S., So, Y. H., LEE, H., VANBUSKIRK, A. M., FENG, N., SHERIDAN, J. F., and STEVENS, V., 1993, Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Journal of Molecular Recognition, 6, 81–94.
  • KOBS-CONRAD, S., LEE, H., DIGEORGE, A. M., and KAUMAYA, P. T. P., 1993, Engineered topographic determinants with alpha beta, beta alpha beta, and beta alpha beta alpha topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4). Journal of Biological Chemistry, 268, 25285–25295.
  • LAIRMORE, M. D., DIGEORGE, A. M., CONRAD, S. F., TREVINO, A. V., LAL, R. B., and KAUMAYA, P. T., 1995, Human T-Iymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immuno-genicity and overcome genetic restriction. Journal of Virology, 69, 6077–6089.
  • NIXON, D. F., HIOE, C., CIIEN, P. D., BIAN, Z., KUEBLER, P., Li, M. L., Qiu, H., Li, X. M., SINGH, M., RICHARDSON, J., McGEE, P., ZAMB, T., KOFF, W., WANG, C. Y., and O'HAGAN, D., 1996, Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 14, 1523–1530.
  • OGAWA, Y., YAMAMOTO, M., OKADA, H., YASHIKI, T., and SHIMAMOTO, T., 1988a, A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chemical and Pharmaceutical Bulletin, 36, 1095–1103.
  • OGAWA, Y., YAMAMOTO, M., TAKADA, S., OKADA, H., and SHIMAMOTO, T., 1988b, Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/ glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer. Chemical and Pharmaceutical Bulletin, 36, 1502–1507.
  • O'HAGAN, D. T., JEFFERY, H., ROBERTS, M. J., McGEE, J. P., and DAVIS, S. S., 1991b, Controlled release microparticles for vaccine development. Vaccine, 9, 768–771.
  • O'HAGAN, D. T., MCGEE, J. P., HOLMGREN, J., MOWAT, A. M., DONACHIE, A. M., MILLS, K. H., GAISFORD, W., RAHMAN, D., and CHALLACOMBE, S. J., 1993, Biodegradable microparticles for oral immunization. Vaccine, 11, 149–154.
  • O'HAGAN, D. T., RAHMAN, D., McGEE, J. P., JEFFERY, H., DAVIES, M. C., WILLIAMS, P., DAVIS, S. S., and CHALLACOMBE, S. J., 1991a, Biodegradable microparticles as controlled release antigen delivery systems. Immunology, 73, 239–242.
  • PALKER, T. J., TANNER, M. E., SCEARCE, R. M., STREILEIN, R. D., CLARK, M. E., and HAYNES, B. F., 1989, Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. Journal of Immunology, 142, 971–978.
  • PANINA-BORDIGNON, P., TAN, A., TERMIJTELEN, A., DEMOTZ, S., CORRADIN, G., and LANZAVECCHIA, A., 1989, Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. European Journal of Immunology, 19, 2237–2242.
  • PARTIDOS, C. D., and STEWARD, M. W., 1990, Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. Journal of General Virology, 17, 2099–2105.
  • PERUMAL, D., DANGOR, C. M., ALcocK, R. S., HURBANS, N., and MOOPANAR, K. R., 1999, Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheres. Journal of Microencapsulation, 16, 475–487.
  • PIQUE, C., CONNAN, F., LEVILAIN, J. P., CHOPPIN, J., and DOKHELAR, M. C., 1996, Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response. Journal of Virology, 70, 4919–4926.
  • Rosimo, V., DEYME, M., BENOIT, J. P., and MADELMONT, G., 1998, Physical aging of progesterone-loaded poly(D,L,-lactide-co-glycolide) microspheres. Pharmaceutical Research, 15, 794–798.
  • ROY, S., SCHERER, M. T., BRINER, T. J., SMITH, J. A., and GEFTER, M. L., 1989, Murine MHC polymorphism and T cell specificities. Science, 244, 572–575.
  • SAH, H., 1999, Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. Journal of Controlled Release, 58, 143–151.
  • SCHWENDEMAN, S. P., CARDAMONE, M., BRANDON, M. R., KLIBANOV, A., and LANGER, R., 1996, Stability of proteins and their delivery from biodegradable polymer microspheres. In Microparticulate systems for the delivery of proteins and vaccines, edited by S. Cohen and H. Bernstein (New York: Marcel Dekker), pp. 1–50.
  • SCHWENDEMAN, S. P., COSTANTINO, H. R., GUPTA, R. K., and LANGER, R., 1997, Progress and challenges for peptide, protein, and vaccine delivery from implantable polymeric systems. In Controlled Drug Delivery: Challenges and Strategies, edited by K. Park (Washington, DC: The American Chemical Society), pp. 229–267.
  • SHENDEROVA, A., BURKE, T. G., and SCHWENDEMAN, S. P., 1999, The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharmaceutical Research, 16, 241–248.
  • SINGH, M., SINGH, A., and TALWAR, G. P., 1991, Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) micro capsules. Pharmaceutical Research, 8, 958–961.
  • SINIGAGLIA, F., GUTTINGER, M., KILGUS, J., DORAN, D. M., MATILE, H., ETLINGER, H., TRZECIAK, A., GILLESSEN, D., and PINK, J. R., 1988, A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature, 336, 778–780.
  • SUGIYAMA, T., KUMAGAI, S., NISIIIDA, T., USHIJIMA, K., MATSUO, T., YAKUSHIJI, M., HYON, S. H., and IKADA, Y., 1998, Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer. Anticancer Research, 18, 2837–2842.
  • UCHIDA, T., GOTO, S., and FOSTER, T., 1994, Particle size studies for subcitaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulations. Journal of Pharmacy and Pharmacology, 47, 556–560.
  • URATA, T., ARIMORI, K., and NAKANO, H., 1999, Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. Journal of Controlled Release, 58, 133–141.
  • WANG, J., and SCIIWENDEMAN, S. P., 1999, Mechanisms of solvent evaporation encapsulation processes: prediction of solvent evaporation rate. Journal of Pharmaceutical Sciences, 88, 1090–1099.
  • Zuu, G., MALLERY, S. R., and SCIIWENDEMAN, S. P., 2000, Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide). Nature Biotechnology, 18, 52–57.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.